Lipum AB (publ) today announces the allocation of warrants in series TO A 2025/2028 and TO B 2025/2028, as resolved at the company’s Annual General Meeting held on June 16, 2025.

During the period June 16 - 30, employees, key consultants, and board members were given the opportunity to subscribe for warrants in Lipum at a price of SEK 2.72 per warrant.

Outcome:

• Number of subscribed warrants: 150,000
• Total number of warrants offered: 168,000
• Subscription rate: 89%
• Number of warrants reserved for future use: 44,000 (62,000)
• Lipum will thus receive approximately SEK 408,000

CEO Comment:
"I am very pleased with the strong interest in the warrant programs and the confidence in Lipum's operations shown by our employees and board members “ said Ola Sandborgh, CEO

Contacts
Ola Sandborgh, CEO
ola.sandborgh@lipum.se
+46 72 218 80 21
Web: www.lipum.se

About Us
Lipum AB (publ) is a clinical stage biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. The lead candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule of the immune system (BSSL). SOL-116 is in clinical phase with a successfully completed Phase 1 study. Together with strong preclinical data, we have a solid foundation for continued development in the treatment of rheumatoid arthritis. Lipum also explores other inflammatory diseases with a high unmet medical need. The company is based in Umeå, an excellent life science cluster in Sweden. Lipum’s unique approach has attracted international attention, including a major European Commission Horizon 2020 grant. The company's share (LIPUM) is traded on the Nasdaq First North Growth Market. Certified Adviser is G&W Fondkommission.

Attachments
Lipum Announces Outcome of Warrant Programs TO A 2025/2028 and TO B 2025/2028

Läs mer på MFN